- Presented data at ESMO 2025 demonstrating promising efficacy with CRB-701 in head and neck squamous cell carcinoma (HNSCC) and cervical cancer
- CRB-701 data for both indications is expected in mid-2026 with focus on durability and patient stratification
- Reported 14-day CRB-913 SAD/MAD data demonstrating potent and rapid weight loss of 2.9% with favorable GI safety
- On schedule to complete 12-week CRB-913 obesity study (n=240) in summer 2026
- Completed
$75 million public offering in Q4 2025 extending cash runway into 2028
"Our encouraging data readouts for CRB-701 and CRB-913 in the fourth quarter of 2025 set the stage for a potentially transformative 2026. This summer we anticipate key data readouts for both programs that we expect will elucidate their differentiated efficacy and safety profiles, as well as potential clinical utility and commercial opportunities,” said
Key Corporate and Program Updates
CRB-701 is a next-generation, highly stable Nectin-4 targeting ADC being developed to treat HNSCC and cervical cancer. The
- Encouraging CRB-701 Phase 1/2 data in Q4 2025. Corbus presented dose optimization data at the 2025
European Society for Medical Oncology Congress (ESMO 2025). Highlights included:- Unconfirmed Objective Response Rate with CRB-701 at the 3.6 mg/kg dose: HNSCC - 47.6%, Cervical cancer - 37.5%, and Bladder - 55.6%.
- Favorable safety and tolerability with no grade 4 or 5 treatment-related adverse events.
- Markedly low levels of peripheral neuropathy and skin toxicity.
- Link here for CRB-701 ESMO data press release and here for archived KOL event discussing the findings.
- Anticipated catalysts for CRB-701 in 2026:
- Provide update in Q1 2026 from discussions with FDA regarding registrational study protocols for HNSCC and cervical cancer.
- Report monotherapy data in mid-2026 with a key focus being durability data and patient stratification.
- Generate CRB-701 + Keytruda combination data in first line (“1L”) HNSCC patients in Q4 2026.
CRB-913 is a highly peripherally restricted oral CB1 inverse agonist for the treatment of obesity.
- Encouraging CRB-913 data in Q4 2025. Corbus completed a single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1a study in
December 2025 . SAD portion: n=64 across 8 cohorts; MAD portion: n=48 across 4 cohorts. Highest SAD dose tested was 600 mg/day and highest MAD dose tested was 150 mg/day. Highlights include:- Weight loss of 2.9% (placebo adjusted) at 14-days in dedicated 150 mg/day obesity cohort (n=12). Weight loss started early and deepened with time. Safe and well-tolerated across all cohorts and all doses studied.
- Very favorable GI profile with no reports of vomiting, constipation or nausea.
- Daily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative.
- Link here for Phase 1a study data press release and here for archived KOL event discussing the findings.
- Anticipated catalyst for CRB-913 in 2026:
- CANYON-1 Phase 1b dose-ranging 12-week study (n=240) expected to be completed in summer 2026.
CRB-601 is an anti-avß8 integrin monoclonal antibody (mAB) designed to block the activation of latent TGFß in the tumor micro-environment to treat solid tumors.
- Phase 1 dose escalation trial of CRB-601 completed in Q4 2025.
- Preliminary monotherapy data were presented in
November 2025 at theSociety for Immunotherapy of Cancer (SITC) 2025. - Corbus has deprioritized this program and does not plan to enroll additional patients.
- Preliminary monotherapy data were presented in
Financial Results for the Quarter and Year Ended
The Company reported a net loss of approximately
Operating expenses increased by
The Company had
About Corbus
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.
INVESTOR CONTACTS:
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com
Managing Director
daniel@lifesciadvisors.com
MEDIA CONTACT:
Founder & Principal
liz@melonecomm.com
---tables to follow---
Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share amounts) | ||||||||||||||||
| Unaudited For the Three Months Ended | For the Year Ended | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 18,406 | $ | 8,787 | $ | 70,095 | $ | 32,222 | ||||||||
| General and administrative | 3,560 | 3,818 | 15,215 | 16,499 | ||||||||||||
| Total operating expenses | 21,966 | 12,605 | 85,310 | 48,721 | ||||||||||||
| Operating loss | (21,966 | ) | (12,605 | ) | (85,310 | ) | (48,721 | ) | ||||||||
| Other income (expense), net: | ||||||||||||||||
| Interest and investment income, net | 1,410 | 1,782 | 5,530 | 6,311 | ||||||||||||
| Interest expense | — | — | — | (1,872 | ) | |||||||||||
| Other income, net | 1 | 1,293 | 1,243 | 4,073 | ||||||||||||
| Total other income, net | 1,411 | 3,075 | 6,773 | 8,512 | ||||||||||||
| Net loss | $ | (20,555 | ) | $ | (9,530 | ) | $ | (78,537 | ) | $ | (40,209 | ) | ||||
| Net loss per share, basic and diluted | $ | (1.25 | ) | $ | (0.78 | ) | $ | (5.90 | ) | $ | (3.68 | ) | ||||
| Weighted average number of common shares outstanding, basic and diluted | 16,482,734 | 12,179,482 | 13,317,116 | 10,915,413 | ||||||||||||
| Comprehensive loss: | ||||||||||||||||
| Net loss | $ | (20,555 | ) | $ | (9,530 | ) | $ | (78,537 | ) | $ | (40,209 | ) | ||||
| Other comprehensive income (loss): | ||||||||||||||||
| Change in unrealized (loss) gain on marketable debt securities | (50 | ) | (172 | ) | (88 | ) | 36 | |||||||||
| Total other comprehensive (loss) income | (50 | ) | (172 | ) | (88 | ) | 36 | |||||||||
| Total comprehensive loss | $ | (20,605 | ) | $ | (9,702 | ) | $ | (78,625 | ) | $ | (40,173 | ) | ||||
Consolidated Balance Sheets (in thousands, except share and per share amounts) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 28,492 | $ | 17,198 | ||||
| Investments | 134,777 | 131,864 | ||||||
| Restricted cash | 670 | 285 | ||||||
| Prepaid expenses and other current assets | 3,015 | 3,629 | ||||||
| Total current assets | 166,954 | 152,976 | ||||||
| Restricted cash | — | 385 | ||||||
| Property and equipment, net | 159 | 385 | ||||||
| Operating lease right-of-use assets | 1,082 | 2,133 | ||||||
| Total assets | $ | 168,195 | $ | 155,879 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 2,215 | $ | 4,786 | ||||
| Accrued expenses | 16,844 | 5,426 | ||||||
| Operating lease liabilities, current | 1,633 | 1,606 | ||||||
| Total current liabilities | 20,692 | 11,818 | ||||||
| Operating lease liabilities, noncurrent | — | 1,633 | ||||||
| Total liabilities | 20,692 | 13,451 | ||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, | — | — | ||||||
| Common stock, 17,611,511 and 12,179,482 shares issued and outstanding at | 2 | 1 | ||||||
| Additional paid-in capital | 702,984 | 619,285 | ||||||
| Accumulated deficit | (555,430 | ) | (476,893 | ) | ||||
| Accumulated other comprehensive (loss) gain | (53 | ) | 35 | |||||
| Total stockholders’ equity | 147,503 | 142,428 | ||||||
| Total liabilities and stockholders’ equity | $ | 168,195 | $ | 155,879 | ||||
